Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 286,497 | 193,618 | 235,184 | 298,257 | 225,670 |
| Marketable Securities | 1,629,213 | 1,527,619 | 1,620,101 | 1,605,569 | 1,709,975 |
| Receivables | N/A | N/A | N/A | 25,000 | N/A |
| TOTAL | $1,929,092 | $1,733,666 | $1,867,611 | $1,937,132 | $1,943,891 |
| Non-Current Assets | |||||
| PPE Net | 120,831 | 124,926 | 129,426 | 134,093 | 138,542 |
| Investments And Advances | 28,412 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 166,973 | 171,119 | 169,065 | 170,809 | 173,697 |
| TOTAL | $316,216 | $296,045 | $298,491 | $304,902 | $312,239 |
| Total Assets | $2,245,308 | $2,029,711 | $2,166,102 | $2,242,034 | $2,256,130 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,798 | 9,753 | 13,064 | 14,709 | 15,578 |
| Accrued Expenses | 87,608 | 74,453 | 85,856 | 41,523 | 48,042 |
| Other current liabilities | N/A | N/A | N/A | 10,417 | 4,824 |
| TOTAL | $118,957 | $104,362 | $119,447 | $87,782 | $89,810 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 1,295 | 2,129 | 3,021 | 3,845 | 4,483 |
| Other Non-Current Liabilities | 198,046 | 201,901 | 205,172 | 209,849 | 214,339 |
| TOTAL | $210,369 | $214,224 | $217,495 | $222,172 | $226,662 |
| Total Liabilities | $329,326 | $318,586 | $336,942 | $309,954 | $316,472 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 95,300 | 90,950 | 86,364 | 85,774 | 85,353 |
| Common Shares | 3,013 | 2,794 | 2,721 | 2,698 | 2,684 |
| Retained earnings | -1,816,938 | -1,710,497 | -1,501,948 | -1,365,952 | -1,328,641 |
| Other shareholders' equity | 4,926 | 3,979 | 4,073 | 1,778 | 10,503 |
| TOTAL | $1,915,982 | $1,711,125 | $1,829,160 | $1,932,080 | $1,939,658 |
| Total Liabilities And Equity | $2,245,308 | $2,029,711 | $2,166,102 | $2,242,034 | $2,256,130 |